Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors

Abstract

received an unrestricted grant of Cristal Therapeutics.Cristianne J.F. Rijcken reports personal fees and non-financial support from Cristal Therapeutics, during the conduct of the study; personal fees from Cristal Therapeutics, outside the submitted work; In addition, Cristianne J.F. Rijcken has 3 patents related to CPC634 issued and is the founder and CSO of Cristal Therapeutics, so well aware of all technological developments as well as employed by the company. Rob Hanssen is an employee of Cristal Therapeutics.

Clinical Translation of Self‐Assembled Cancer Nanomedicines

“…The study emerged with skin toxicity at high doses (>60 mg m −2 ), though CPC634 were safe in general, demonstrating a maximum tolerated dose of 70 mg m −2 and a recommended phase 2 dose of 60 mg m −2 . [118] Besides, CPC634 demonstrated dose-related pharmacokinetic profiles, exhibiting significant higher levels of DTX in both plasma and tumors compared to conventional DTX, [119] which may be achieved by the reduced protein corona on the nanocarriers as illustrated in a recent study. [120] Moreover, CPC634 were further labeled with zirconium-89 ( 89 Zr) to assess the biodistribution and retention in tumors in patients with tumors that failed to standard therapy.…”

Highway to Success—Developing Advanced Polymer Therapeutics

“…Reduced plasma docetaxel Cmax and AUC and improved safety were observed from the CPC634 micelle. [ 170 ]…”

“…Reduced plasma docetaxel Cmax and AUC and improved safety were observed from the CPC634 micelle. [170] Ferumoxytol (an FDA-approved 30 nm iron oxide nanoparticles for anemia) has been used as a companion diagnostic, for liposomal irinotecan, Onivyde in patients with solid tumors. The study demonstrated that higher ferumoxytol accumulation levels as determined by magnetic resonance imaging correlated with greater lesion size reductions.…”

<p>Phytochemical-Based Nanomedicine for Advanced Cancer Theranostics: Perspectives on Clinical Trials to Clinical Use</p>

“…80 Another recent report the author demonstrated that CPC634 nanoparticles (75 mg/m2, for 2 cycles) increased, sustained, and prolonged intratumoral concentration of drug docetaxel by 25%, lowering grade 3 and grade 4 neutropenia cases in solid tumor patients. 81…”